ArticleInternational journal of hematology-oncology and stem cell research2013
Copper status in patients with thalassemia major in zahedan, iran.
Article in International journal of hematology-oncology and stem cell research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 17 citations in OpenAlex.
- The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial.Annals of hematology · 2021Trial
- Sodium, Magnesium, Calcium, Manganese, Iron, Copper, and Zinc in Serums of Beta Thalassemia Major Patients.Biological trace element research · 2021Article
- A Cross-Sectional Study of Glycemic Status and Zinc Level in Patients with Beta-Thalassemia Major.International journal of hematology-oncology and stem cell research · 2017Article
- The selenium status in thalassemia patients in South East of iran.International journal of hematology-oncology and stem cell research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere have been many reports and papers on deficient, normal and high levels of copper in patients with thalassemia major. The aim of this study is to evaluate copper status in a series of more than 300 patients with thalassemia major and determine the degree of copper deficiency or excess.
methodsThree hundred and seventy patients with thalassemia major over 5 years of age were enrolled in this study. All patients were asked to fast for 12 hours before the test. Measurement was performed using atomic-absorption spectrophotometer in 2012 in southeast of Iran.
resultsThe study included both males (n = 192) and females (n = 141). Of whom, 90 (27%) were aged 5-10 yrs, 80 (24%) were aged 10-15 yrs and 49% were above 15 years of age. Iron chelation therapy was dessferroxamine, deferasirox and dessferroxamine and deferiprone combinations in 61.5 %( 204 cases), 24.2%( 82 cases) and 14.3%( 47 cases), respectively. Among the 370 cases, 107 (32.1%) had copper deficiency, 73 (21.9%) had copper excess and 153 (45.9%) had normal copper level.
conclusionHigh percentage of copper deficiency was documented in 333 patients with thalassemia major and about 50% of patients had normal copper level. This finding showed the importance of micronutrient measurement in thalassemic patients for treatment planning in every part of the world.
Indexed as
Identifiers
24505531PMC3913146W2134877160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.